Theoretical and Computational Molecular Biophysics, Biochemistry, and Physical Chemistry Our group develops and applies advanced computational algorithms and theoretical formalisms to tackle diverse problems in molecular biophysics, biochemistry, and physical chemistry. We seek an understanding of fundamental processes in organic and biological systems in molecular, atomisitic, and electronic detail. The theme of our research is to quantitatively describe how the thermal environment drives molecular and biomolecular motions (molecular dynamics) and then to examine how such motions might modulate physicochemical processes in nature and technology. Please visit our group webpage: (venkatramanilab.weebly.com) to find out about our active projects. Students in the lab will be exposed to an interdisciplinary research environment with the opportunity to learn rigorous theoretical formalisms and state-of-the-art high performance computational tools.

Steel panel radiator with right or left bottom connection. RADIK VKU is a steel panel radiator in VENTIL KOMPAKT version which allows left or right bottom connection to a pressurized heating system. There are no hangers welded at the back side of the radiator therefore the radiators in. Rolandas Strazdas of Vilnius Gediminas Technical University, Vilnius (VGTU) with expertise in: Communication and Media, Institutional Economics and International Economics. Read 49 publications.

Computational methods include molecular modeling and simulations (coarse grained, atomistic, and hybrid quantum mechanics molecular mechanics) in conjunction with accelarated sampling strategies. Students will learn to describe processes such as charge transport, optical response of molecules, and energy flow in organic frameworks using the theory of open quantum systems within a reduced density matrix framework.

Close collaboration with experimental colleagues is a crucial component of our research and helps us realize our goals. Students will be encouraged to develop an understanding of the latest experimental techniques associated with their research area with a view towards developing predictive algorithms and proposing novel experiments to probe emerging concepts. • Yadav, A., Paul, S. Venkatramani, R., Koti, A.S.R. Differences in the mechanical unfolding pathways of apo- and copper-bound azurins.

Activator for windows 7 professional. Scientific Reports, 8:1989 (2018) • Mandal, I., Paul, S., Venkatramani, R. Optical Backbone-Sidechain Charge Transfer Transitions in Proteins Sensitive to Secondary Structure and Modifications. Faraday Discussions, 207, 115 - 135 (2018) • Prasad, S., Mandal, I., Paul, A., Mandal, B., Venkatramani, R., Swaminathan, R. Near UV-Visible Electronic Absorption Originating from Charged Amino Acids in a Monomeric Protein. Chemical Science, 8, 5416 (2017) • Seth, C., Kaliginedi*, V., Suravarapu, S., Reber, D., Hong, W., Wandlowski, T., Lafolet, F., Broekmann, P., Royal, G., Venkatramani, R. Conductance in a Bis-Terpyridine Based Single Molecular Breadboard Circuit.

Chemical Science, 8, 1576 (2016) • Venkatramani, R., Wierzbinski, E., Waldeck, D. H., and Beratan, D.

Breaking the simple proportionality between molecular conductances and charge transfer rates. Faraday Discussions, 174, 57 (2014).

Primary objective: To assess the early signals for anti-tumor activity (i.e. Objective response rate, progression-free survival) of pembrolizumab in combination with vorinostat in patients with advanced prostate, renal or urothelial cell carcinoma. Secondary objectives: (1) To evaluate the overall safety profile of pembrolizumab in combination with vorinostat; (2) To assess the safety and tolerability of pembrolizumab in combination with vorinostat in patients with advanced prostate, renal or urothelial cell carcinoma in order to select the recommended Phase 2 Dose (RP2D); (3) To characterize immune cell subsets, and miRs in tumor and/or blood. Condition or disease Intervention/treatment Phase Renal Cell Carcinoma Urinary Bladder Neoplasms Drug: Pembrolizumab Drug: Vorinostat Phase 1. This is a Phase I/Ib, open-label, safety, and pharmacodynamics study of pembrolizumab in combination with vorinostat in patients with advanced prostrate, renal or urothelial cell carcinoma. This clinical study will be composed of a Dose Finding Phase and an Expansion Phase.

The Dose Finding Phase will estimate the Recommended Phase II Dose (RP2D) in patients with advanced renal and urothelial cell carcinoma patients. The Dose Finding Phase will lead to the identification of an Expansion Test Dose for pembrolizumab in combination with vorinostat. The Expansion Test Dose will be the Recommended Phase II Dose (RP2D) (i.e. The highest tested dose that is declared safe and tolerable by the Investigators and Sponsor). Patients will be treated with oral vorinostat every day for 14 days, and with pembrolizumab at the fixed dose of 200 mg IV. Each cycle is every 21 days. Two dose levels of vorinostat will be tested in 2-patient cohorts according to the 3 + 3 standard design (100 mg and 200 mg).